References
PRO-C1
Levels of ECM biomarkers over time in untreated controls and nitisinone-treated patients. Estimated geometric means with 95% confidence intervals. Demographics and clinical characteristics of the patients included in the SONIA 2 biomarker analysis. Statistical significance: * Concentration of the biomarkers (median and 95% confidence interval (CI)) in the control and nitisinone groups at baseline and at end of study (Year 4). CTX-I, PRO-C1 and C2M (ng/mL), and CTX-II normalized by levels of urine creatinine (CTX-II/Creat) (ng/mmol). Statistically significant differences: ** Level of biomarkers at baseline by sex. CTX-I, PRO-C1 and C2M (ng/mL), and CTX-II normalized by levels of urine creatinine (CTX-II/Creat) (ng/mmol). Statistical significance: *** Level of biomarkers at baseline by age. CTX-I, PRO-C1 and C2M (ng/mL), and CTX-II normalized by levels of urine creatinine (CTX-II/Creat) (ng/mmol). Statistical significance: *** Level of biomarkers by cAKUSSI at baseline. CTX-I, PRO-C1 and C2M (ng/mL), and CTX-II normalized by levels of urine creatinine (CTX-II/Creat) (ng/mmol). Statistical significance: *** Biomarkers measured in the SONIA 2 study, description, and normal range (levels in healthy individuals).